Compare Autozone Inc (AZO) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autozone Inc vs IDEXX Laboratories, Inc. — how do they compare? Autozone Inc trades at $3,040.71 (market cap $49.67B), while IDEXX Laboratories, Inc. trades at $571.64 (market cap $46.22B). The key difference: Autozone Inc and IDEXX Laboratories, Inc. are close in size by market cap, and Autozone Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| AZO | IDXX | |
|---|---|---|
Market Cap | $49.67B | $46.22B |
Sector | Consumer Cyclical | Health |
52-Week High | $4.35K | $766.68 |
52-Week Low | $2.92K | $526.44 |
Enterprise Value | $62.05B | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AutoZone (AZO) trades at $3,038.29, down 0.97% on the day, with technical indicators showing a bearish trend. The company maintains strong fundamentals with $18.94B in revenue and 12.4% net income margin, though profit margins have declined from 14.94% in 2022 to 13.19% in 2025. Recent earnings show mixed results with Q3 2025 missing expectations but Q1 2026 beating estimates. Analyst sentiment remains strongly bullish with 32 buy ratings and a consensus price target of $3,730.
AZO presents a compelling value opportunity with solid cash flow generation and dominant market position, though investors face risks from margin compression and competitive pressures. The stock's current valuation at 20.93 P/E appears reasonable given the company's consistent profitability and analyst optimism, but requires monitoring of international expansion execution and macroeconomic impacts on consumer spending.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
